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D dimer, a degradation product of cross-linked fibrin, 
is generated by lysis of fibrin but not by lysis of fibrinogen 
and can be reliably detected by specific monoclonal an-
tibody techniques. The generation of D dimer after in-
travenous streptokinase in acute myocardial infarction 
was studied with the use of a semiquantitative latex ag-
glutination immunoassay. This assay utilizes the mono-
clonal antibody DD-386/22, raised by conventional hy-
bridoma technology, against a highly purified preparation 
of human D dimer and is adjusted to give a positive 
agglutination at a D dimer serum concentration of greater 
than 200 ng/ml (upper limit of normal). 
Twenty-one patients with acute transmural myo-
cardial infarction of less than 3 hours' duration were 
studied. Fifteen patients received 0.75 to 1.5 million U 
intravenous streptokinase and 6 patients were treated 
conventionally without thrombolytic therapy. An ele-
Thrombolytic therapy with streptokinase during acute myo-
cardial infarction characteristically results in elevated serum 
levels of fibrinogen and fibrin degradation products, which 
are primarily a consequence of systemic fibrinogenolysis 
(1-4) and, to a lesser extent, of fibrinolysis of the occlusive 
coronary artery thrombus (5-7). Although routine assays 
do not distinguish between the degradation products of fi-
brinogen and fibrin, new immunoassays that utilize mono-
clonal antibodies raised against the unique antigenic deter-
minants of cross-linked fibrin can be used to specifically 
measure the degradation products of cross-linked fibrin (XDP) 
without being influenced by the degradation products of 
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vated serum level of D dimer was detected before treat-
ment in only 1 of 15 patients receiving intravenous strep-
tokinase and within 2 hours of treatment in the remaining 
14 patients who received streptokinase. In contrast, an 
elevated serum D dimer level was not detected during 
the first 24 hours in any of the six conventionally treated 
patients, including two patients who manifested the clin-
ical syndrome of spontaneous reperfusion. 
The data suggest that in patients with acute myo-
cardial infarction, an elevated serum level of D dimer, 
a cross-linked fibrin degradation product occurs early 
after administration of a large dose of streptokinase, but 
is infrequent during the first 24 hours in conventionally 
treated patients with acute infarction. Measurement of 
D dimer may be potentially useful for monitoring throm-
bolysis in patients with acute myocardial infarction. 
(J Am Coil CardioI1986;7:1320-4) 
fibrinogen (8-10). The D dimer is one of these degradation 
products of cross-linked fibrin which is stable and resists 
further digestion by plasmin (6,7,11). Elevated serum levels 
of D dimer have been found in patients with pathologic 
fibrinolysis (12) and after streptokinase-induced thrombo-
lysis in patients with deep venous thrombosis or pulmonary 
embolus (13). The purpose of this study was to examine 
whether lysis of coronary thrombus in patients with acute 
myocardial infarction would produce detectable elevated 
serum levels of D dimer. 
Methods 
Study patients. The study group comprised 21 patients 
with acute myocardial infarction who fulfilled the following 
criteria: 1) chest pain of less than 3 hours' duration at the 
time of evaluation by the cardiology team; 2) ST segment 
elevation indicative of transmural ischemia; and 3) persis-
tence of both the chest pain and the electrocardiographic 
changes after sublingual nitroglycerin. Myocardial infarc-
0735-1097/86/$3.50 
JACC Vol 7, No 6 
June 19861320-4 
tion was confirmed in all 21 patients by elevated serum 
creatine kinase activity and by evolutionary changes of in-
farction on the electrocardiogram. 
Intravenous streptokinase group. Fifteen patients (12 
male, 3 female) aged 59 ± 8 years (range 45 to 70), in 
whom. there were no contraindications to thrombolytic or 
anticoagulant therapy and in whom consent was obtained 
from both the patient's physician and the patient, were in-
cluded in a prospective study of intravenous streptokinase 
therapy during acute myocardial infarction (14). Nine pa-
tients had anterior infarction and six had inferior infarction. 
Pretreatment coronary angiography was not performed so 
as not to delay the initiation of thrombolytic therapy. After 
a 40 U/kg intravenous bolus of heparin, 750,000 U strep-
tokinase was infused into a peripheral vein at a rate of 250 
to 500 U/kg per minute (mean 390 ± 70). Six of the 15 
patients received a second infusion of 750,000 U strepto-
kinase at the same rate as the first infusion commencing 5 
to 74 minutes after completion of the first infusion. Im-
mediately after administration of streptokinase, all patients 
received a continuous infusion of heparin targeted to a partial 
thromboplastirt time of between 80 and 100 seconds. 
The recognition of reperfusion was based on the close 
temporal occurrence of the nonangiographic criteria of relief 
of chest pain, rapid resolution of ST segment elevation and 
an abrupt rise and rapid washout of creatine kinase (15); 
coronary artery patency was assessed within 4 days by coro-
nary angiography. Thirteen patients had nonangiographic 
evidence of reperfusion; of these, II patients had throm-
bolysis in myocardial infarction trial (TIMI) grade 3 per-
fusion of the infarct artery at delayed angiography, I patient 
had TIMI grade 2 perfusion and I patient, in whom there 
were clinical signs of reocclusion before angiography, had 
an occluded infarct artery. The remaining two patients, both 
with anterior infarction, had no nonangiographic evidence 
of reperfusion and both patients had a total thrombotic oc-
clusion of the left anterior descending artery at angiography 
performed within 2 hours of administration of streptokinase. 
No streptokinase group. Six patients (five male, one fe-
male) aged 71 ± 8 years (range 56 to 77) did not receive 
streptokinase either because thrombolytic therapy was con-
traindicated (n = 5) or because consent was denied (n = 
I). Three patients had anterior infarction and three had in-
ferior infarction. Five patients received low dose heparin 
(10,000 U/day intravenously) and one patient received full 
dose intravenous heparin. 
Detection of elevated serum D dimer. Blood samples 
were drawn in all patients on admission and at 4 to 6 hour 
intervals thereafter for 24 hours. In 13 of the 15 patients 
who received streptokinase, a sample of blood was also 
collected during the 30 minute period after the completion 
of 750,000 U streptokinase, and in the 2 remaining patients 
a sample was collected within 2 hours of streptokinase 
administration. In all six patients who received a second 
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infusion of 750,000 U streptokinase, the first poststrepto-
kinase blood sample was obtained before commencement 
of the second infusion. 
The procedure for blood collection was asfollows: blood 
was drawn either by atraumatic venipuncture or from art 
indwelling brachial plastic cannula with an attached three-
way stopcock and heparin lock. When the latter technique 
was used, the line was first flushed with 3 to 5 ml of normal 
saline solution immediately before aspiration of blood, and 
the first 5 ml of blood was discarded. A 3 to 5 ml aliquot 
of blood was placed into a standard fibrinogen and fibrin 
degradation product tube containing thrombin and epsilon 
aminocaproic acid. The sample was placed into a container 
of ice for transportation to the laboratory and was then 
I 
incubated at 37°C for 30 minutes to prevent in vitro fibri-
nolysis. Some blood samples that were collected during the 
second half of the 24 hour collection period were refrigerated 
at 2 to 8°C for a period not exceeding 12 hours before 
incubation. Serum was separated by centrifugation at 2,500 
rpm for 10 minutes at room temperature and then imme-
diately frozen at - 20° C for a period not exceeding 4 weeks. 
Immediately before assay, the serum was thawed at room 
temperature. No specimen was frozen and thawed more than 
once before assay. 
The presence of D dimer was detected by a latex agglu-
tination immunoassay (Dimertest Latex)* that utilizes a 
monoclonal antibody (DD-3B6/22) which has been found 
to be highly specific for the recognition of the breakdown 
products of human cross-linked fibrin (9,10). This mono-
clonal antibody was raised by conventional hybridoma tech-
nology using a highly purified preparation of human D dimer 
to react with an antigenic site at or near the gamma iso-
peptide linkage present in human cross-linked fibrin. This 
antigenic site is preserved in the D dimer and in some other 
breakdown products of human cross-linked fibrin but is not 
present in the fibrinogen molecule or in the breakdown prod-
ucts of fibrinogen or noncross-linked fibrin, including the 
D monomer (9). 
The sensitivity of the reagent was adjusted to give pos-
itive agglutination at a serum concentration of D dimer of 
greater than 200 ng/ml (upper limit of normal). The range 
of D dimer concentration in any given specimen was es-
tablished by serial doubling dilution of the sample in phos-
phate buffered saline solution (pH 7.4), tested as outlined 
in the assay procedure and expressed as either not detectable 
or the highest dilution of serum in which agglutination was 
observed. Therefore, agglutination in undiluted serum cor-
responded to a concentration of greater than 200 ng/ml; in 
dilutions of 1 : 2, 1: 4 and 1: 8, agglutination corresponded 
to concentrations of greater than 400 ng/ml, greater than 
800 ng/ml and greater than 1,600 ng/ml, respectively. All 
the assays were performed by one investigator (L.B.). 
*Kmdly supplied as a gIft by American Diagnostica Inc. 
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Results 
Intravenous streptokinase group (Table 1). In 14 of 
the IS patients, there was no detectable serum level of D 
dimer on admission, but all 14 patients, including the 2 
patients in whom reperfusion did not occur, had an elev~tion 
of serum level of D dimer after intravenous streptokmase 
adm'inistration. In only one patient was an elevated serum 
level of D dimer found on admission and in this patient the 
titer doubled within 30 minutes of administration of 750,000 
U streptokinase. 
In 13 of the 14 patients without detectable D dimer on 
admission, an elevated serum D dimer level was detected 
in the first sample collected after administration of 750,000 
U streptokinase. In 11 patients this sample was coll~ct~d 
within 30 minutes (mean 11 ± 13) and in 2 patients wlthm 
2 hours after administration of streptokinase. In the re-
maining patient (case 6), D dimer was not detected following 
administration of the first 750,000 U infusion of strepto-
kinase but was detected immediately after administration 
of a se~ond 750,000 U infusi~n of st~eplokinase. This patient 
had a very high pretreatment anti streptokinase antibody tit~r 
apd the first infusion of streptokinase did not produce a lytIC 
state or achieve reperfusion, but after the second infusion 
of streptokinase there was both depletion of fibrinogen and 
clinical and angiogtaphic evidence of reperfusion. 
Both patients in whom reperfusion did not occur had an 
elevation of serum D dimer after streptokinase administra-
tion, suggesting that streptokinase had some fibrinolytic ac-
tion in these two patients. In one patient (case 13), there 
was a high antistreptokinase titer and, following adminis-
tration of 1.5 million U streptokinase, there was an atten-
uated lytic state and only a brief, 1 hour elevation of se~m 
D dimer. In the other patient (case 15), a long OCclusIve 
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thrombus of the left anterior descending artery was seen at 
early angiography. 
The elevation of serum D dimer persisted for more than 
24 hours in five patients, for more thqn 12 hours in seven 
patients, for more than 8 hours in two patients and for only 
1 hour in one patient (case 13, see t;arlier). 
Repeat streptokinase infusion group. In this study, the 
six patients who received a second infusion of streptokinase 
(cases 4,6,7, II, 13 and IS) did not have higher serum 
levels of D dimer than those of the nine patients who re-
ceived one infusion. Except for Patient 6, in whom the first 
dose of streptokinase was probably inactivated, the second 
dose of streptokinase had no discernible influence on serum 
D dimer. Of note, however, the one patient (case II) in 
whom a reocclusion at 12 hours was treated with a second 
infusion of streptokinase had a distinct reelevation of serum 
D dimer after retreatment. 
No streptokinase group. None of the six conventionally 
treated patients had a detectable elevated serum level of D 
dimer either on admission or during the subsequent 24 hours. 
Two of these six patients manifested the clinical syndrome 
of spontaneous reperfusion. Both patients had spontaneous 
early improvement in chest pain associated with significant 
ST segment resolution, and in both patients creatine kinase 
activity peakeq early, within 10 hours of the onset of chest 
pain (16). Coronary angiography was performed within 24 
hours of admission in the first patient and 6 weeks after 
infarction in the second patient. In both patients, the infarct 
artery was patent but significantly stenosed. 
Discussion 
Several investigators (4,6,12) have suggested that mea-
surement of the degradation products of cross-linked fibrin 
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(XDP) would be useful for monitoring the effects of throm-
bolytic therapy, but we are unaware of any reports in which 
degradation products of cross-linked fibrin were measured 
after thromboiytic therapy in acute myocardial infarction. 
Elevjlted serum levels of D dimer after coronary 
thrombolysis. Our data indicate that after administration 
of hi&h doses of intravenous strepto\<.inase to patients with 
acute myocardial infarction, the process of fibrinolysis usu-
ally results in a significant increase in serum levels of deg-
radation produGtsor'cross-linked fibrin, even when coronary 
artery'reperfusion is pot achieved. Although the elevated 
serum levels of D dimer in this study cannot be specifically 
related to thrombolysis of the coronary thrombi that caused 
the acute infarction, it seems unlikely that D dimer was 
generated by thrombolysis at aI)Y other s~te in these pa~ients 
for the following reasons: I) no patient had clinical evidence 
of peripheral thrombosis; 2) patients at risk of having an 
intracardiac thrombus were specifically excluded from our 
protocol and no evidence of intracardiac thrombus was de-
I 
tected in any of the seven patients who underwent a two-
dimensional echocardiographic assessment befote strepto-
kinase administration; 3) no patient had any bleeding prob-
lems during the 12 hours after streptokinase administration 
that would suggest lysis of a hemostatic thrombus elsewhere 
in the body; 4) all patients were admith~d within 3 hours of 
the onset of symptoms of ipfarction and, before streptoki-
nase administration, had not been subjected to any procedure 
likely to promote the formation of a fibrin thrombus: and 
5) all patients received a large dose of heparin shortly after 
admission and before streptokinase, so that it is unlikely 
that significant thrombus would have formed at the site of 
venipuncture and placement of the small venous cannula. 
Spe~i~cit~ Qf the immunoassay used in this study. In 
contrast to the measurement of D dimer, the measurement 
of total fibrinogen and fibrin degradation products by routine 
assays would not be useful for monitoring thrombolysis after 
infusion of streptokinase or any other agent that causes 
fibrinogenolysis. In this study, the serum level of fibrinogen 
and fibrin degradation products after streptokinase was in-
variably greater than 200 jLg/ml which is two or three orders 
of magnitude greater than the levels of D dimer. Therefore, 
after high dose intravenous streptokinase administration, the 
contribution of degradation products of cross-linked fibrin 
from thrombolysis to the elevated total fibrinogen and fibrin 
degradation products is very small compared with the effect 
of fibrinogenolysis. 
For the same reason, it is important that assays designed 
to study clot lysis specifically measure the breakdown prod-
ucts of fibrin and not of fibrinogen. Although earlier im-
munoassays were not highly specific for the breakdown 
products of cross-linked fibrin and did cross-react with the 
degradation products of fibrinogen and non-cross-linked fi-
brin (7-9), the monoclonal antibody DD-3B6/22 that is the 
basis of the immunoassay used in this study has been re-
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ported to be highly specific for the recognition of breakdown 
products of human cross-linked fibrin (XDP) and does not 
react with fibrinogen or the degradation products of fibrin-
ogen or non-cross-linked fibrin (9,10). The persistence of 
a high titer of fibrinogen degradation products for longer 
than the period of elevation of D dimer in this study is 
further evidence that this assay did not recognize the deg-
radation products of fibrinogen. 
The specificity of this assay would probably also be im-
portant for monitoring therapy with clot-selective agents, 
because at high doses, these agents usually have some sys-
temic lytic effect and cause some degree of fibrinogenol-
ysis (17). 
The elevation of serum D dimer levels in the two patients 
in whom reperfusion was not achieved does not necessarily 
impiy a lack of specificity. because coron1ll)' thrombolysis 
is not necessarily synonymous with reperfusion. The find-
irigs in these two patients may not be false positive results, 
but ratner may reflect partial or incomplete clot lysis such 
that there is an elevation of D dimer without reperfusion. 
Indeed, in this study there was frequently evidence of clot 
lysis (an elevation of D dimer) noted before any sigl1s of 
reperfusion. 
Spontaneous reperfusion. Of interest, two of the six 
conventionally treated patients developed the clinical syn-
prome of spontaneous reperfusion but 'qid not have a de-
tectable elevation of serum D dime~. Although the absence 
of detectable p dimer with' the assay used in this study does 
not definitively rule out a small degree Df endogenous throrn-
bolys'is producing a D dimer level of less than 200 ng/ml, 
t~e absence of detectable D dimer in these two patients 
sllggests that the clinical syndrome of spontaneous reper-
fusion is probably not due to endogenous thrombolysis of 
an·occlusive thrombus and therefore, at least quantitatively, 
is significantly different from streptokinase-induced throm-
bolysis. 
In our opinion, it is more likely that patients with the 
~yndrome of spontaneous reperfusion characterized by pat-
ency of the artery of infarction, preserved left ventricular 
function and early washout of creatine kinase may represent 
a subpolmlation of patients whose artery of infarctiol1 has 
been partially patent from the outset, with superimposed 
int~rrnittent occlusion due to coronary artery spasm or tran-
sient platelet aggregation, or both (18). 
Study limitations. The limitation of using a semiquan-
titative assay has already been discussed; however, because 
only one patient had a detectable elevation of serum D dimer 
unrelated to administration of streptokinase, it appears that 
the sensitivity of this assay is adequate for monitoring the 
process of fibrinolysis in patients with acute myocardial 
infarction. Although data in a control group of patients who 
did not have coronary thrombosis and who received strep-
tokinase may have been informative, no appropriate group 
could be identified because it was not acceptable to admin-
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ister streptokinase to patients without acute myocardial in-
farction, and patients with noncoronary thrombotic condi-
tions would evolve an elevation of serum D dimer after 
streptokinase-induced lysis of the thrombus (13). 
Clinical implications. The data suggest that measure-
ment of D dimer, a degradation product of cross-linked 
fibrin, may be a potentially useful techniq!Je for monitoring 
the process of fibrinolysis during thrombolytic therapy in 
patients with acute myocardial infarction. 
We life grateful to Gloria Solomon and Ann Lew for research assistance. 
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